Managing Haematopoietic Stem Cell Transplantation Pre- and Post-Apheresis

• Managing Haematopoietic Stem Cell Transplantation Pre- and Post-Apheresis

AUTHOR(S)

Sysmex Europe GmbH

SUMMARY

Haematopoietic stem cell transplantation, or HSCT, is a very effective therapy for haematological malignancies, tumours and other diseases. It’s also a challenging procedure for clinicians and associated with certain risks for the patients. During HSCT, patients’ haematopoietic systems are sup-pressed by chemotherapy or radiotherapy and replaced with either stem cells previously harvested from this patient or with cells from another individual (donor). One of the treatment’s benefits is that it lets one use more vigorous therapies in patients with resistant tumours. In addition, the transplanted cells themselves may have a curative effect on the patient’s haematological malignancies.

HSCT is defined by the following phases:
■ Chemotherapy (in autologous HSCT) followed by stem cell mobilisation by cytokine regimens
■ Collecting stem cells by apheresis
■ Post-processing of the apheresis product
■ Intensive chemotherapy of the patient
■ Reinfusing stem cells
■ Engrafting in the bone marrow after the stem cell infusion

This white paper looks at the pre- and post-apheresis stages of HSCT. It addresses the challenges and points out the added value an XN haematology analyser can deliver in this context.

NOTE(S)

Design and specifications may be subject to change due to further product development.
Changes are confirmed by their appearance on a newer document and verification according to its date of issue.